drugset / Trial / NCT00805233

Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration

NCT00805233

RandomizedParallel-groupOpen-labelTreatment

Summary

This open-label, randomized, Phase II research study will look to see whether an investigational treatment combining bromfenac ophthalmic drops with ranibizumab intravitreal injection is safe and effective for treating wet AMD as compared to ranibizumab alone.

Timeline

Start
2008-12
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bromfenac Other / unclassified Other
Subject Ranibizumab Monoclonal antibody Intravitreal